Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697674 | 1.00 | KMT2A (0.57) | KMT2ARAB9AMEN1TDP1PDE4A | |
| SCHEMBL19083821 | 0.86 | TAS1R3 (0.53) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL31389146 | 0.82 | TAS1R3 (0.63) | KMT2AMEN1TAS1R3TAS1R1 | |
| SCHEMBL26148924 | 0.82 | TAS1R3 (0.63) | KMT2AMEN1TAS1R3TAS1R1 | |
| SCHEMBL19084001 | 0.80 | TAS1R3 (0.61) | KMT2ARAB9AMEN1TDP1PDE4A | |
| SCHEMBL20697830 | 0.80 | TAS1R3 (0.61) | KMT2ARAB9AMEN1TDP1PDE4A | |
| SCHEMBL23118386 | 0.75 | KMT2A (0.54) | KMT2ARAB9AMEN1TDP1PDE4A | |
| SCHEMBL19083826 | 0.72 | POLB (0.67) | KMT2ARAB9AMEN1TDP1PDE4A | |
| SCHEMBL19075737 | 0.71 | POLB (0.69) | KMT2ARAB9AMEN1TDP1PDE4A | |
| SCHEMBL31389134 | 0.70 | TAS1R3 (0.68) | KMT2AMEN1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | KMT2A 1836/4885RAB9A 915/4885MEN1 1465/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | KMT2A 1836/4885RAB9A 915/4885MEN1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.